Clinical trial registry record

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 31, 2015.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00877032
Last registry update
March 31, 2015
Status
Completed
Phase
Phase 1
Sponsor
Pfizer
Enrollment
57
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · SINGLE GROUP · PREVENTION · QUADRUPLE
Evidence population
Human clinical study registration
Participants
57
Population
ALL · 18 Years
Duration
2009-04-01 to 2011-07-01
Intervention
RN6G; Placebo
Comparator
Not reported
Outcomes measured
Incidence and Severity of Ocular Adverse Events (AEs) — Baseline up to Day 168; Incidence and Severity of Systemic Adverse Events (AEs) — Baseline up to Day 168; Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - Inf)] of RN6G — Pre-dose on Day 1; 1 hour (…; Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of RN6G — Pre-dose on Day 1; 1 hour…; Maximum Observed Plasma Concentration (Cmax) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on Day 1; 0, 1, 4…; Time to Reach Maximum Observed Plasma Concentration (Tmax) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on…; Volume of Distribution (Vd) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on Day 1; 0, 1, 4, 8, 12 hrs post-…; Clearance (CL) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on Day 1; 0, 1, 4, 8, 12 hrs post-dose on Day 1…; Mean Residence Time (MRT) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on Day 1; 0, 1, 4, 8, 12 hrs post-do…; Plasma Terminal Half-life (t1/2) of RN6G — Pre-dose on Day 1; 1 hour (hr) during infusion on Day 1; 0, 1, 4, 8, 12 hrs…; Maximum Observed Plasma Concentration (Cmax) of Amyloid (A) Beta(1-X) — Pre-dose on Day 1; 1 hour (hr) during infusion…; Time to Reach Maximum Observed Plasma Concentration (Tmax) of Amyloid (A) Beta(1-X) — Pre-dose on Day 1; 1 hour (hr) du…; Area Under the Curve From Time Zero to Day 165 [AUC (0-165d)] of Amyloid (A) Beta(1-X) — Pre-dose on Day 1; 1 hour (hr)…; Number of Participants With Anti-Drug Anti-body — Baseline up to Day 168
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON